替吉奥治疗结直肠癌的近期临床疗效及对远期预后的影响

The short-term effect of tegafur in the treatment of colorectal cancer and the impact on long-term prognosis

目的 探讨替吉奥联合奥沙利铂方案治疗晚期结直肠癌的近期疗效及对远期预后的影响.方法 选取70例晚期结直肠癌患者为研究对象,采用随机数字表法分为替吉奥组（奥沙利铂联合替吉奥治疗）和卡培他滨组（奥沙利铂联合卡培他滨治疗）,每组35例.对比两组近期疗效、毒副反应及2年生存率及中位生存时间.结果 替吉奥组的总有效率85.71％,卡培他滨组为77.14％,两组差异无统计学意义（χ2=0.850,P=0.356）.治疗后,两组患者血清血管内皮生长因子（VEGF）水平较治疗前均显著降低（t=21.694、20.558,P=0.001、0.001）,替吉奥组的VEGF水平与卡培他滨组比较差异无统计学意义（t=0.998、1.242,P=0.305、0.249）;替吉奥组的1年生存率为51.43％、2年生存率为25.71％,与卡培他滨组的45.71％、17.14％比较差异无统计学意义（χ2=0.229、0.764,P=0.632、0.382）;吉奥组的中位生存时间13.5个月,与卡培他滨组的13.0个月比较差异无统计学意义（Z=1.304,P=0.752）.替吉奥组的手足综合征发生率为5.71％,低于卡培他滨组的22.86％（χ2=4.163,P=0.027）.结论 替吉奥联合奥沙利铂方案治疗晚期结直肠癌效果与卡培他滨联合奥沙利铂方案效果相似,并发症发生率有所降低.

Objective To evaluate the short -term effect of tegafur combined with oxaliplatin in the treatment of advanced colorectal cancer and its impact on long -term prognosis .Methods 70 patients with advanced colorectal cancer were selected .The patients were randomly divided into tegafur group （ oxaliplatin plus tegafur ） and capecitabine group （ oxaliplatin combined with capecitabine ） according to the digital table ,35 cases in each group , The short-term efficacy,side effects,2-year survival rate and median survival time were compared between the two groups.Results The total effective rate of the tegafur group was 85.71％, which of the capecitabine group was 77.14％,but the difference was not statistically significant between the two groups （χ2 =0.850,P=0.356）.After treatment,the levels of VEGF in the two groups were significantly lower than those before treatment （ t =21.694, 20.558,P=0.305,0.249）.There was no statistically significant difference between the two groups （t =0.998, 1.242,P=0.281,0.307）.The 1-year survival rate was 51.43％and the 2-year survival rate was 25.71％of the tegafur group,compared with 45.71％ and 17.14％ in the capecitabine group ,the differences were not statistically significant （χ2 =0.229,0.764,P=0.632,0.382）.The median survival time of the tegafur group was 13.5 months, which of the capecitabine group was 13.0 months,there was no statistically significant difference （ Z=1.304,P=0.752）.The incidence rate of hand -foot syndrome of the tegafur group was 5.71％,which was lower than 22.86％of the capecitabine group （χ2 =4.163,P=0.027）.Conclusion The efficacy of tegafur combined with oxaliplatin in the treatment of advanced colorectal cancer is similar to capecitabine plus oxaliplatin , with a slightly lower complication rate.